S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities
Retail sales surge 0.7% in March as Americans seem unfazed by higher prices with jobs plentiful
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities
Retail sales surge 0.7% in March as Americans seem unfazed by higher prices with jobs plentiful
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities
Retail sales surge 0.7% in March as Americans seem unfazed by higher prices with jobs plentiful
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities
Retail sales surge 0.7% in March as Americans seem unfazed by higher prices with jobs plentiful

Pharvaris (PHVS) Competitors

$20.15
-1.75 (-7.99%)
(As of 04/15/2024 ET)

PHVS vs. CNTX, GRFS, LVTX, MYNZ, TLSA, ATNFW, SXTPW, ACONW, AIMDW, and DRTSW

Should you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include Context Therapeutics (CNTX), Grifols (GRFS), LAVA Therapeutics (LVTX), Mainz Biomed (MYNZ), Tiziana Life Sciences (TLSA), 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Aclarion (ACONW), Ainos (AIMDW), and Alpha Tau Medical (DRTSW). These companies are all part of the "medical" sector.

Pharvaris vs.

Pharvaris (NASDAQ:PHVS) and Context Therapeutics (NASDAQ:CNTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, community ranking, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Pharvaris is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PharvarisN/AN/A-$109.18M-$2.84-7.10
Context TherapeuticsN/AN/A-$23.96M-$1.50-1.01

Pharvaris has a beta of -3.12, indicating that its stock price is 412% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 2.17, indicating that its stock price is 117% more volatile than the S&P 500.

Pharvaris presently has a consensus target price of $32.50, indicating a potential upside of 61.29%. Context Therapeutics has a consensus target price of $4.00, indicating a potential upside of 164.90%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Context Therapeutics is more favorable than Pharvaris.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharvaris
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Context Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Pharvaris received 21 more outperform votes than Context Therapeutics when rated by MarketBeat users. Likewise, 63.27% of users gave Pharvaris an outperform vote while only 58.82% of users gave Context Therapeutics an outperform vote.

CompanyUnderperformOutperform
PharvarisOutperform Votes
31
63.27%
Underperform Votes
18
36.73%
Context TherapeuticsOutperform Votes
10
58.82%
Underperform Votes
7
41.18%

14.0% of Context Therapeutics shares are owned by institutional investors. 9.4% of Context Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Pharvaris had 20 more articles in the media than Context Therapeutics. MarketBeat recorded 22 mentions for Pharvaris and 2 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 1.44 beat Pharvaris' score of 0.51 indicating that Context Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Pharvaris Positive
Context Therapeutics Positive

Pharvaris' return on equity of -47.92% beat Context Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
PharvarisN/A -47.92% -44.45%
Context Therapeutics N/A -115.50%-97.04%

Summary

Context Therapeutics beats Pharvaris on 9 of the 15 factors compared between the two stocks.

Get Pharvaris News Delivered to You Automatically

Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PHVS vs. The Competition

MetricPharvarisPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market CapN/A$6.42B$4.73B$7.59B
Dividend YieldN/A3.10%5.44%3.96%
P/E Ratio-7.106.78176.6113.93
Price / SalesN/A316.042,473.7189.08
Price / CashN/A20.2533.1228.20
Price / Book4.085.544.674.26
Net Income-$109.18M$137.95M$99.83M$211.03M
7 Day Performance-12.92%-5.17%-4.36%-4.55%
1 Month Performance-13.70%-4.47%-3.17%-2.06%
1 Year Performance131.61%2.78%12.55%6.74%

Pharvaris Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CNTX
Context Therapeutics
2.7734 of 5 stars
$1.31
+0.8%
$4.00
+205.3%
+141.7%$0.00N/A-0.875
GRFS
Grifols
3.6502 of 5 stars
$7.18
-1.5%
$10.50
+46.2%
-13.1%$0.00$7.13B0.0026,314
LVTX
LAVA Therapeutics
2.5811 of 5 stars
$2.71
-8.1%
$6.00
+121.4%
+64.6%$0.00$6.77M-1.7069Positive News
MYNZ
Mainz Biomed
1.9369 of 5 stars
$0.99
-8.3%
$6.00
+506.1%
-83.5%$0.00$530,000.000.0058
TLSA
Tiziana Life Sciences
0.6435 of 5 stars
$0.45
+4.7%
N/A-53.3%$0.00N/A0.009Positive News
Gap Up
ATNFW
180 Life Sciences
0 of 5 stars
$0.01
flat
N/A-59.0%$0.00N/A0.004Positive News
Gap Up
SXTPW
60 Degrees Pharmaceuticals
0 of 5 stars
$0.11
flat
N/AN/A$0.00$90,718.000.002Positive News
ACONW
Aclarion
0 of 5 stars
$0.03
-44.4%
N/A-52.9%$0.00$75,404.000.004Gap Down
High Trading Volume
AIMDW
Ainos
0 of 5 stars
$0.06
flat
N/A-76.1%$0.00$122,112.000.0046Gap Up
High Trading Volume
DRTSW
Alpha Tau Medical
0 of 5 stars
$0.26
+4.0%
N/A-16.0%$0.00N/A0.00121Short Interest ↓
Gap Up

Related Companies and Tools

This page (NASDAQ:PHVS) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners